Somatic mutations of signaling genes in non-small-cell lung cancer.

[1]  Masahide Takahashi,et al.  p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma , 2004, Cancer.

[2]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[3]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[4]  R. Wilson,et al.  Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4 , 2007, PloS one.

[5]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[6]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[7]  Jie Liang,et al.  Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer , 2009, Clinical Cancer Research.

[8]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Zuquan Zou,et al.  A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. , 2009, International journal of molecular medicine.

[11]  M. Mcdermott,et al.  The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[12]  Randall T Moon,et al.  Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways , 1999, Oncogene.

[13]  D. Ma,et al.  Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. , 2010, Biochemical and biophysical research communications.

[14]  S. Toyooka,et al.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[17]  M. Higashiyama,et al.  Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer , 1998, Oncogene.

[18]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Earle,et al.  Management Issues for Stage IV Non-Small Cell Lung Cancer. , 1997, Cancer control : journal of the Moffitt Cancer Center.

[20]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[21]  D. Schiff,et al.  XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. , 2010, IDrugs : the investigational drugs journal.

[22]  M. Varella‐Garcia,et al.  ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[24]  G. Delsol,et al.  Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis , 2001, Oncogene.

[25]  P. Laurent-Puig,et al.  Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation , 2006, The American journal of surgical pathology.

[26]  F. Shepherd,et al.  Second line chemotherapy for NSCLC: establishing a gold standard. , 2002, Lung cancer.

[27]  M. Loda,et al.  Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. , 2009, Cancer research.

[28]  A. Iafrate,et al.  Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. , 2007, The Journal of molecular diagnostics : JMD.

[29]  A. Marchetti,et al.  FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K‐ras mutations , 1998, The Journal of pathology.

[30]  M. Wasik,et al.  Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. , 2001, Cancer research.

[31]  Young-Kwang Yoon,et al.  KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach , 2010, Molecular carcinogenesis.

[32]  J. Settleman,et al.  Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion , 2008, Cell cycle.

[33]  Maira Sauveur-Michel,et al.  HER2が増幅されPI3K3CAが変異した乳癌細胞におけるPI3K/mTor二重阻害剤NVP‐BEZ235による特異的アポトーシス誘発 , 2009 .

[34]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[35]  F. de Marinis,et al.  Toxicity of targeted therapy in non-small-cell lung cancer management. , 2009, Clinical lung cancer.

[36]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[37]  D. Ryberg,et al.  p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  A. Mutirangura,et al.  Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[39]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[40]  M. Stratton,et al.  LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition , 2009, British Journal of Cancer.

[41]  T. Mok,et al.  Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer , 2009, Pathology & Oncology Research.

[42]  P. Nederlof,et al.  EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Li Ding,et al.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.

[45]  P. Hainaut,et al.  Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. , 2007, Cancer research.

[46]  S. Sommer,et al.  Epidemiology of Doublet/Multiplet Mutations in Lung Cancers: Evidence that a Subset Arises by Chronocoordinate Events , 2008, PloS one.

[47]  T. Asahara,et al.  Accumulation of β-Catenin Protein and Mutations in Exon 3 of β-Catenin Gene in Gastrointestinal Carcinoid Tumor , 2001 .

[48]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[49]  Chang Ho Kim,et al.  TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer , 2010, Journal of Korean medical science.

[50]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  T. Asahara,et al.  Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. , 2001, Cancer research.

[52]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[53]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Y. Miyagi,et al.  Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. , 2007, American journal of clinical pathology.

[55]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[56]  J. Soh,et al.  The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer , 2007, Clinical Cancer Research.

[57]  R. Salgia,et al.  Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation , 2006, Nature Clinical Practice Oncology.

[58]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[59]  V. Miller,et al.  Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. , 2010, Oncology.

[60]  Dong Sun Kim,et al.  PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.

[61]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[62]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[63]  P. Jänne.  Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. , 2008, Lung cancer.

[64]  F. Cappuzzo,et al.  Clinical implications of MET gene copy number in lung cancer. , 2010, Future oncology.

[65]  M. Socinski,et al.  Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[66]  V. Hirsh.  Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. , 2010, Current oncology.

[67]  M. Ratain,et al.  Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Goya,et al.  Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[70]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[71]  H. Lane,et al.  Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.

[72]  J. Neal,et al.  First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. , 2010, Clinical advances in hematology & oncology : H&O.

[73]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[74]  K. Smalley.  PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. , 2010, Current opinion in investigational drugs.

[75]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[76]  P. Bunn,et al.  Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.

[77]  T. Oyama,et al.  Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking , 2006, British Journal of Cancer.

[78]  P. Keohavong,et al.  Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non‐small cell lung cancer patients , 2009, Molecular carcinogenesis.

[79]  G Cartei,et al.  Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[80]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Goldman,et al.  Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  S S Sommer,et al.  EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids , 2008, Oncogene.

[83]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[84]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[85]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[86]  G. Rossi,et al.  EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. , 2009, American journal of clinical pathology.

[87]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[88]  Igor Goryanin,et al.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.

[89]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.